Vaxcyte (PCVX) Current Assets (2019 - 2026)

Vaxcyte (PCVX) has 8 years of Current Assets data on file, last reported at $1.8 billion in Q1 2026.

• Current Assets for Q1 2026 came in at $1.8 billion, up 5.65% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.8 billion (up 5.65% YoY), and the FY2025 annual result was $1.6 billion, down 8.98% from the prior year.
• Current Assets improved to $1.8 billion in Q1 2026 per PCVX's latest filing, from $1.6 billion in the prior quarter.
• Over five years, Current Assets peaked at $2.2 billion in Q3 2024 and troughed at $342.2 million in Q1 2022.
• A 5-year average of $1.3 billion and a median of $1.5 billion in 2024 frame the typical range for Current Assets.
• The sharpest annual moves came in 2022 and 2025: Current Assets surged 267.69% in 2022, then slipped 20.18% in 2025.
• A 5-year view of Current Assets shows it stood at $942.6 million in 2022, then increased by 16.27% to $1.1 billion in 2023, then jumped by 63.14% to $1.8 billion in 2024, then slipped by 8.98% to $1.6 billion in 2025, then rose by 11.44% to $1.8 billion in 2026.
• Business Quant data shows PCVX's Current Assets at $1.8 billion in Q1 2026, $1.6 billion in Q4 2025, and $1.8 billion in Q3 2025.